APA

Chevallier P., Robillard N., Charbonnier A., Raffoux E., Maury S., Carras S., Chabrot C., Fohrer C., Bernard M., Blade J., Etienne A., Talmant P., Delaunay J., Guillaume T., Mohty M., Bene M., Ifrah N. & Dombret H. (20120521). Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. : Blood.

Chicago

Chevallier Patrice, Robillard Nelly, Charbonnier Aude, Raffoux Emmanuel, Maury Sebastien, Carras Sylvain, Chabrot Cecile, Fohrer Cecile, Bernard Marc, Blade Jean-Sebastien, Etienne Anne, Talmant Pascaline, Delaunay Jacques, Guillaume Thierry, Mohty Mohamad, Bene Marie-Christine, Ifrah Norbert and Dombret Herve. 20120521. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. : Blood.

Harvard

Chevallier P., Robillard N., Charbonnier A., Raffoux E., Maury S., Carras S., Chabrot C., Fohrer C., Bernard M., Blade J., Etienne A., Talmant P., Delaunay J., Guillaume T., Mohty M., Bene M., Ifrah N. and Dombret H. (20120521). Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. : Blood.

MLA

Chevallier Patrice, Robillard Nelly, Charbonnier Aude, Raffoux Emmanuel, Maury Sebastien, Carras Sylvain, Chabrot Cecile, Fohrer Cecile, Bernard Marc, Blade Jean-Sebastien, Etienne Anne, Talmant Pascaline, Delaunay Jacques, Guillaume Thierry, Mohty Mohamad, Bene Marie-Christine, Ifrah Norbert and Dombret Herve. Trastuzumab for treatment of refractory/relapsed HER2-positive adult B-ALL: results of a phase 2 GRAALL study. : Blood. 20120521.